<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341377</url>
  </required_header>
  <id_info>
    <org_study_id>SCCHEC-02-2017-042</org_study_id>
    <nct_id>NCT03341377</nct_id>
  </id_info>
  <brief_title>Perioperative Symptom Study of Lung Cancer</brief_title>
  <official_title>An Observational Study for Establishing the Perioperative Symptom Management Cohort for Patients With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaojun Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zigong First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangyou People’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dazhu County People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Chengdu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Seventh People's Hospital of Chengdu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Cancer Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators propose a prospective cohort study to develop and validate essential technical
      parameters for establishing the patient-reported outcome-based perioperative symptom
      management cohort in patients with lung cancer. With 300 patients with lung cancer who are
      going to have surgery, this study will administrate symptom assessments (MDASI-LC) before
      surgery (typically within 3 days before surgery), daily after surgery (in hospital ≤ 14
      days), and weekly after discharge, up to 4 weeks (±3 days) or the start day of postoperative
      oncologic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2017</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 17, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative symptom burden (severity, freqency and impact on daily functioning) measured by MDASI-LC</measure>
    <time_frame>less than 6 weeks</time_frame>
    <description>We will use MD Anderson Symptom Inventory lung cancer module (MDASI-LC) to longitudinally assess the perioperative symptom burden for lung cancer patients. The symptom burden will be profiled as symptom severity, frequency of moderate to severe symptom and its interference with daily functioning.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">512</enrollment>
  <condition>Patient-reported Outcomes</condition>
  <arm_group>
    <arm_group_label>Perioperative lung cancer cohort</arm_group_label>
    <description>Real-world symptom management for surgical patients with lung cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lung cancer patient undergoing surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be pathologically or clinically diagnosed as primary lung cancer before surgery;

          2. Plan to undergo a surgical procedure.

        Exclusion Criteria:

          1. Aged younger than 18;

          2. Diagnosis of cognitive impairment or unable to understand the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sichuan Cancer Hospital and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sichuan Cancer Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Seventh People's Hospital of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Chengdu</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dazhu County People's Hospital</name>
      <address>
        <city>Dazhou</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangyou People's Hospital</name>
      <address>
        <city>Jiangyou</city>
        <state>Sichuan</state>
        <zip>621700</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zigong First People's Hospital</name>
      <address>
        <city>Zigong</city>
        <state>Sichuan</state>
        <zip>643000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Cancer Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Xiaojun Yang</investigator_full_name>
    <investigator_title>Clinical Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>utility parameter</keyword>
  <keyword>patient-reported outcome</keyword>
  <keyword>perioperative symptom management</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

